Key Points
- Director Casey Tansey purchased 15,821 Mobia Medical shares at an average $11.66 each, investing approximately $184,473 and increasing their ownership by 5.88% to 284,725 shares.
- Mobia Medical reported quarterly revenue of $13.51 million, up 102.4% year over year, but its adjusted EPS loss of $1.10 missed the $0.83 consensus estimate.
- Analyst sentiment remains a “Moderate Buy”, with a consensus price target of $20.75, despite ratings ranging from “sell” to “buy.”
Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) Director Casey Tansey purchased 15,821 shares of the company's stock in a transaction dated Friday, August 14th. The stock was purchased at an average price of $11.66 per share, for a total transaction of $184,472.86. Following the completion of the purchase, the director owned 284,725 shares in the company, valued at approximately $3,319,893.50. The trade was a 5.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Mobia Medical Stock Performance
Mobia Medical stock opened at $11.74 on Tuesday. The stock has a market capitalization of $390.84 million and a PE ratio of -0.61. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. Mobia Medical, Inc. has a one year low of $10.19 and a one year high of $15.29. The firm's fifty day moving average price is $12.42.
Mobia Medical (NASDAQ:MOBI - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. Mobia Medical's revenue was up 102.4% compared to the same quarter last year. As a group, sell-side analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently issued reports on MOBI. Weiss Ratings started coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They issued a "sell (e-)" rating on the stock. Wall Street Zen raised shares of Mobia Medical from a "sell" rating to a "hold" rating in a report on Sunday, June 14th. Zacks Research upgraded shares of Mobia Medical to a "hold" rating in a research report on Wednesday, June 3rd. BTIG Research reiterated a "buy" rating and set a $19.00 price target on shares of Mobia Medical in a research note on Wednesday, August 12th. Finally, Wolfe Research initiated coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set an "outperform" rating for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.75.
Read Our Latest Research Report on Mobia Medical
Mobia Medical Company Profile
(
Get Free Report)
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
